NAD+ Quick Start
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, central to energy metabolism, mitochondrial function, and DNA repair. It is a substrate for sirtuins and PARP enzymes, and cellular NAD+ declines with age. Note: NAD+ is a coenzyme, not a peptide. It is studied via injection, IV, and intranasal routes, alongside oral precursors (NMN/NR).
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
NAD+ Dosing Protocols
The injectable (subcutaneous) and nasal-spray formats are documented as two separate protocols. NAD+ doses are in the milligram range and are commonly researched a few times weekly. Ranges are research-planning references, not personal dosing recommendations. NAD+ is notably prone to flushing and nausea when delivered too quickly, so slow administration is standard.
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Low | 50 mg | 2–3× weekly |
| Standard | 100 mg | 2–3× weekly |
Nasal Spray (≈2× the injection mg)
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Low | 100 mg | 5 sprays | 2–3× weekly |
| Standard | 200 mg | 10 sprays | 2–3× weekly |
NAD+ Reconstitution Guide
NAD+ ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use. NAD+ solutions are often slightly colored and very water-soluble.
Injection
| BAC | Conc. | 50 mg |
|---|---|---|
| 10 mL | 100 mg/mL | 0.5 mL · 50 u |
| 5 mL | 200 mg/mL | 0.25 mL · 25 u |
The NAD+ vial holds up to ~10 mL; more dilution (10 mL) is gentler for slow SubQ. Units are U-100.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder.
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 10 mL into the vial for injection (the NAD+ vial holds up to ~10 mL).
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until fully dissolved.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
How NAD+ Works
NAD+ is a coenzyme that shuttles electrons in the redox reactions of cellular energy production (glycolysis, the TCA cycle, and oxidative phosphorylation). Beyond metabolism, it is the required substrate for sirtuins (linked to stress resistance and longevity signaling), PARP enzymes (DNA repair), and CD38. Because tissue NAD+ declines with age and metabolic stress, raising NAD+ availability is a central theme in longevity research.
Energy metabolism
Essential electron carrier for ATP production in mitochondria.
Sirtuins
Required substrate for sirtuin enzymes implicated in stress resistance and aging.
DNA repair
Substrate for PARP enzymes involved in repairing DNA damage.
Open question
Whether raising NAD+ delivers durable clinical benefits in humans is unsettled.
Who Should Avoid NAD+
Pregnancy & lactation
No human safety data in this context.
Active cancer
NAD+ metabolism intersects with cell proliferation; discuss with a clinician.
Cardiovascular sensitivity
Rapid delivery can cause flushing and chest tightness; caution with cardiac conditions.
Anyone seeking a treatment
NAD+ is a research compound, not a medical treatment.
NAD+ Side Effects & Safety
Rate-dependent reactions
Flushing, nausea, cramping, and chest tightness are classic with fast IV/injection; slowing delivery reduces them.
Injection-site stinging
SubQ NAD+ can sting; more dilution and slow injection help.
Nasal irritation
The concentrated spray can irritate nasal mucosa; alternate nostrils.
Quality-control risk
Verify identity and purity against a Certificate of Analysis.
Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| During dosing | Flushing/nausea, injection-site response | Slow the delivery rate if reactions occur. |
| Week 1–4 | Energy/wellbeing self-report | Subjective; no validated NAD+-specific marker. |
| Ongoing | General metabolic context | Interpret with a clinician; routine labs aren't NAD+-specific. |
Research Evidence Context
Precursor trials
Most human data involves oral precursors (NR/NMN) raising blood NAD+ markers; clinical-endpoint data is mixed.
Direct NAD+ routes
IV/SubQ NAD+ is widely used in wellness settings but has limited controlled outcome data.
Aging biology
Strong preclinical rationale via sirtuin/PARP biology and age-related NAD+ decline.
Open question
Optimal route, dose, and durable benefit in humans remain unresolved.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | More stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. NAD+ degrades faster in solution than many peptides. |
| Appearance | Clear, may be faintly colored | Discard if cloudy or heavily discolored. |
Mistakes & Troubleshooting
- Flushing / nausea. Almost always rate-related — slow the injection or reduce per-dose amount.
- Injection-site stinging. Use the 10 mL (100 mg/mL) reconstitution and inject slowly; the spray is a gentler-feeling alternative for some researchers.
- Spray vs injection dose. The spray runs at ~2× the injection mg to offset lower nasal absorption (≈50–75%); still treat the two routes as separate protocols.
- Left out overnight. Treat reconstituted solution as compromised and discard.
NAD+ vs Precursors
| Feature | NAD+ (direct) | NMN / NR (precursors) |
|---|---|---|
| Form | The coenzyme itself | Building blocks converted to NAD+ |
| Route | IV / SubQ / intranasal | Usually oral |
| Evidence | Limited controlled outcome data | More human data on raising NAD+ markers |
Frequently Asked Questions
What is NAD+?
A coenzyme central to energy metabolism, DNA repair, and sirtuin activity. It is not a peptide.
How is the injection dosed vs the nasal spray?
Separate protocols. Injection commonly references 50–100 mg SubQ, 2–3× weekly. Because nasal absorption is roughly 50–75% of injection, the spray runs at about double — 100–200 mg per dose. At 20 mg per spray (5 mL fill) that is 5–10 sprays, 2–3× weekly, to deliver a comparable systemic amount.
Why does NAD+ cause flushing?
Flushing, nausea, and chest tightness are typically rate-related; delivering NAD+ slowly markedly reduces them.
How is NAD+ reconstituted?
For injection, 1000 mg in 10 mL BAC water (the NAD+ vial holds up to ~10 mL) gives 100 mg/mL, so 50 mg = 0.5 mL = 50 units; the extra dilution is gentler for slow SubQ. The spray ships pre-mixed and delivers 20 mg per spray.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
References
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules. Cell Metab (2018).
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol (2021).
- Martens CR, et al. NR supplementation and NAD+ metabolome. Nat Commun (2018).
- Conlon N, et al. Intravenous NAD+ in humans: pharmacokinetics. Front / J (review).